 Cassidy Delaney
Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 12 | 2025 | 1735 | 2.810 |
Why?
| | Platelet Activation | 4 | 2025 | 82 | 2.460 |
Why?
| | Vascular Remodeling | 3 | 2025 | 181 | 1.780 |
Why?
| | Serotonin | 5 | 2024 | 318 | 1.760 |
Why?
| | Blood Platelets | 4 | 2025 | 369 | 1.620 |
Why?
| | Hypoxia | 5 | 2025 | 1031 | 1.430 |
Why?
| | Bronchopulmonary Dysplasia | 3 | 2022 | 375 | 1.310 |
Why?
| | Receptor, Serotonin, 5-HT2A | 3 | 2020 | 20 | 1.170 |
Why?
| | Lung | 10 | 2025 | 3741 | 1.000 |
Why?
| | Superoxide Dismutase | 4 | 2025 | 322 | 0.970 |
Why?
| | Ductus Arteriosus | 2 | 2023 | 71 | 0.950 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 2024 | 25 | 0.930 |
Why?
| | Bleomycin | 4 | 2020 | 240 | 0.870 |
Why?
| | Hypertrophy, Right Ventricular | 3 | 2022 | 133 | 0.870 |
Why?
| | Pulmonary Artery | 3 | 2015 | 1028 | 0.850 |
Why?
| | Ductus Arteriosus, Patent | 1 | 2023 | 49 | 0.800 |
Why?
| | Platelet Factor 4 | 3 | 2025 | 32 | 0.590 |
Why?
| | Protective Agents | 1 | 2018 | 38 | 0.580 |
Why?
| | Animals, Newborn | 5 | 2022 | 805 | 0.570 |
Why?
| | Nitric Oxide | 2 | 2019 | 886 | 0.540 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 717 | 0.490 |
Why?
| | Pneumonia | 1 | 2020 | 599 | 0.470 |
Why?
| | Pulmonary Alveoli | 2 | 2020 | 366 | 0.440 |
Why?
| | Mice | 10 | 2025 | 16579 | 0.430 |
Why?
| | Animals | 16 | 2025 | 34501 | 0.430 |
Why?
| | Endothelial Cells | 2 | 2015 | 701 | 0.410 |
Why?
| | Mice, Knockout | 4 | 2025 | 2752 | 0.390 |
Why?
| | Hernia, Diaphragmatic | 1 | 2012 | 69 | 0.380 |
Why?
| | Intestinal Obstruction | 1 | 2012 | 48 | 0.380 |
Why?
| | Mice, Inbred C57BL | 8 | 2025 | 5257 | 0.360 |
Why?
| | Ketanserin | 3 | 2018 | 12 | 0.350 |
Why?
| | Fetus | 2 | 2013 | 758 | 0.350 |
Why?
| | Disease Models, Animal | 4 | 2025 | 3943 | 0.340 |
Why?
| | Sertraline | 3 | 2016 | 30 | 0.330 |
Why?
| | Infant, Newborn | 4 | 2024 | 5687 | 0.320 |
Why?
| | Tryptophan Hydroxylase | 2 | 2022 | 54 | 0.300 |
Why?
| | Sheep | 2 | 2022 | 827 | 0.240 |
Why?
| | Schistosoma | 1 | 2024 | 23 | 0.230 |
Why?
| | Complement C5a | 1 | 2024 | 67 | 0.230 |
Why?
| | Complement C3a | 1 | 2024 | 40 | 0.230 |
Why?
| | Schistosomiasis | 1 | 2024 | 38 | 0.230 |
Why?
| | Fluoxetine | 2 | 2016 | 52 | 0.220 |
Why?
| | Extracellular Matrix | 3 | 2025 | 497 | 0.210 |
Why?
| | Hyaluronic Acid | 1 | 2025 | 212 | 0.210 |
Why?
| | Indomethacin | 1 | 2023 | 77 | 0.210 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2023 | 80 | 0.210 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 2 | 2013 | 10 | 0.200 |
Why?
| | Ibuprofen | 1 | 2023 | 80 | 0.200 |
Why?
| | Creatinine | 1 | 2024 | 475 | 0.200 |
Why?
| | Infant, Extremely Premature | 1 | 2023 | 60 | 0.200 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 128 | 0.190 |
Why?
| | Inflammation | 3 | 2025 | 2664 | 0.190 |
Why?
| | Complement System Proteins | 1 | 2024 | 306 | 0.190 |
Why?
| | Complement Activation | 1 | 2024 | 364 | 0.190 |
Why?
| | Selenoproteins | 1 | 2020 | 7 | 0.180 |
Why?
| | Chemokine CCL5 | 1 | 2020 | 42 | 0.180 |
Why?
| | Vascular Resistance | 2 | 2013 | 369 | 0.180 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2019 | 120 | 0.180 |
Why?
| | Male | 9 | 2025 | 62883 | 0.180 |
Why?
| | Macrophages, Alveolar | 2 | 2024 | 379 | 0.180 |
Why?
| | Macrophages | 2 | 2025 | 1463 | 0.170 |
Why?
| | Aurothioglucose | 1 | 2020 | 7 | 0.170 |
Why?
| | Air | 1 | 2020 | 36 | 0.170 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 147 | 0.170 |
Why?
| | Endotoxemia | 1 | 2020 | 83 | 0.170 |
Why?
| | Extracellular Fluid | 1 | 2019 | 31 | 0.160 |
Why?
| | Hyperoxia | 1 | 2020 | 87 | 0.160 |
Why?
| | Herpes Zoster | 1 | 2023 | 317 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2024 | 2065 | 0.160 |
Why?
| | Thrombocytopenia | 1 | 2020 | 182 | 0.150 |
Why?
| | Neovascularization, Physiologic | 1 | 2020 | 172 | 0.150 |
Why?
| | Female | 8 | 2024 | 68127 | 0.150 |
Why?
| | Serotonin Antagonists | 1 | 2018 | 31 | 0.150 |
Why?
| | Administration, Inhalation | 1 | 2019 | 664 | 0.150 |
Why?
| | Case-Control Studies | 1 | 2024 | 3326 | 0.140 |
Why?
| | Receptors, Serotonin | 2 | 2016 | 33 | 0.130 |
Why?
| | Ventricular Pressure | 1 | 2015 | 43 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 81 | 0.120 |
Why?
| | Vasoconstriction | 1 | 2016 | 186 | 0.120 |
Why?
| | Oxidative Stress | 2 | 2025 | 1188 | 0.120 |
Why?
| | Infant | 2 | 2023 | 8913 | 0.120 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2015 | 201 | 0.120 |
Why?
| | Stroke | 1 | 2023 | 1064 | 0.110 |
Why?
| | Apoptosis | 2 | 2020 | 2437 | 0.110 |
Why?
| | Sheep, Domestic | 1 | 2013 | 34 | 0.110 |
Why?
| | Ventricular Function, Right | 1 | 2015 | 272 | 0.100 |
Why?
| | Biomarkers | 1 | 2024 | 3881 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2015 | 501 | 0.100 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2015 | 224 | 0.100 |
Why?
| | Humans | 8 | 2024 | 128524 | 0.100 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2013 | 183 | 0.100 |
Why?
| | Liver | 1 | 2020 | 1827 | 0.100 |
Why?
| | Hysterotomy | 1 | 2011 | 10 | 0.100 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2011 | 28 | 0.090 |
Why?
| | Oxadiazoles | 1 | 2011 | 34 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2012 | 301 | 0.090 |
Why?
| | Phosphorylation | 1 | 2015 | 1681 | 0.090 |
Why?
| | Diseases in Twins | 1 | 2012 | 176 | 0.090 |
Why?
| | rho-Associated Kinases | 1 | 2011 | 83 | 0.090 |
Why?
| | Death, Sudden, Cardiac | 1 | 2012 | 179 | 0.090 |
Why?
| | Cells, Cultured | 2 | 2019 | 4008 | 0.080 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2012 | 204 | 0.080 |
Why?
| | Piperazines | 1 | 2011 | 334 | 0.080 |
Why?
| | Indoles | 1 | 2011 | 367 | 0.080 |
Why?
| | Respiratory Insufficiency | 1 | 2012 | 311 | 0.080 |
Why?
| | Pyridines | 1 | 2011 | 469 | 0.070 |
Why?
| | Gene Expression | 1 | 2013 | 1462 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1943 | 0.070 |
Why?
| | Phenotype | 1 | 2015 | 3050 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2266 | 0.070 |
Why?
| | Hemodynamics | 1 | 2011 | 1083 | 0.070 |
Why?
| | Signal Transduction | 2 | 2020 | 4829 | 0.060 |
Why?
| | Cellular Reprogramming | 1 | 2024 | 95 | 0.050 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2025 | 245 | 0.050 |
Why?
| | Pregnancy | 2 | 2016 | 6297 | 0.050 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2025 | 417 | 0.050 |
Why?
| | Exosomes | 1 | 2023 | 96 | 0.050 |
Why?
| | Plasma | 1 | 2023 | 201 | 0.050 |
Why?
| | Glutathione Peroxidase | 1 | 2020 | 41 | 0.040 |
Why?
| | Selenium | 1 | 2020 | 36 | 0.040 |
Why?
| | Thrombosis | 1 | 2023 | 321 | 0.040 |
Why?
| | Hepatocytes | 1 | 2020 | 213 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2023 | 330 | 0.040 |
Why?
| | Spleen | 1 | 2020 | 513 | 0.040 |
Why?
| | Glutathione | 1 | 2020 | 334 | 0.040 |
Why?
| | Acute Disease | 1 | 2020 | 968 | 0.030 |
Why?
| | Up-Regulation | 1 | 2020 | 826 | 0.030 |
Why?
| | Fibrosis | 1 | 2019 | 522 | 0.030 |
Why?
| | Myography | 1 | 2016 | 4 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 326 | 0.030 |
Why?
| | Persistent Fetal Circulation Syndrome | 1 | 2016 | 136 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 937 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 881 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1398 | 0.030 |
Why?
| | Risk Assessment | 1 | 2023 | 3256 | 0.030 |
Why?
| | Aorta | 1 | 2016 | 407 | 0.030 |
Why?
| | Kidney | 1 | 2020 | 1305 | 0.030 |
Why?
| | DNA | 1 | 2020 | 1392 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1669 | 0.020 |
Why?
| | Adult | 1 | 2013 | 35315 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 2674 | 0.020 |
Why?
|
|
Delaney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|